SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis
Europe - FRA:SRT3 - DE0007165631
224.8 EUR
+1.8 (+0.81%)
SRT3 gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 18 industry peers in the Life Sciences Tools & Services industry. SRT3 may be in some trouble as it scores bad on both profitability and health. SRT3 is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SRT3 had positive earnings in the past year.
SRT3 had a positive operating cash flow in the past year.
SRT3 had positive earnings in each of the past 5 years.
In the past 5 years SRT3 always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.39%, SRT3 is doing worse than 83.33% of the companies in the same industry.
Looking at the Return On Equity, with a value of 5.01%, SRT3 is doing worse than 77.78% of the companies in the same industry.
The Return On Invested Capital of SRT3 (4.71%) is worse than 77.78% of its industry peers.
SRT3 had an Average Return On Invested Capital over the past 3 years of 8.34%. This is significantly below the industry average of 13.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.39% | ||
| ROE | 5.01% | ||
| ROIC | 4.71% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
1.3 Margins
With a Profit Margin value of 3.80%, SRT3 is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
In the last couple of years the Profit Margin of SRT3 has declined.
With a Operating Margin value of 14.06%, SRT3 is not doing good in the industry: 72.22% of the companies in the same industry are doing better.
SRT3's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 46.48%, SRT3 is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
In the last couple of years the Gross Margin of SRT3 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.06% | ||
| PM (TTM) | 3.8% | ||
| GM | 46.48% |
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
SRT3 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
SRT3 has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SRT3 has been increased compared to 5 years ago.
Compared to 1 year ago, SRT3 has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.31 indicates that SRT3 is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.31, SRT3 is doing worse than 61.11% of the companies in the same industry.
The Debt to FCF ratio of SRT3 is 8.92, which is on the high side as it means it would take SRT3, 8.92 years of fcf income to pay off all of its debts.
SRT3 has a worse Debt to FCF ratio (8.92) than 72.22% of its industry peers.
SRT3 has a Debt/Equity ratio of 1.28. This is a high value indicating a heavy dependency on external financing.
SRT3 has a Debt to Equity ratio of 1.28. This is amonst the worse of the industry: SRT3 underperforms 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.28 | ||
| Debt/FCF | 8.92 | ||
| Altman-Z | 2.31 |
ROIC/WACC0.59
WACC7.95%
2.3 Liquidity
A Current Ratio of 0.95 indicates that SRT3 may have some problems paying its short term obligations.
With a Current ratio value of 0.95, SRT3 is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
A Quick Ratio of 0.49 indicates that SRT3 may have some problems paying its short term obligations.
With a Quick ratio value of 0.49, SRT3 is not doing good in the industry: 88.89% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.49 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 59.34% over the past year.
The earnings per share for SRT3 have been decreasing by -11.87% on average. This is quite bad
The Revenue has been growing slightly by 5.82% in the past year.
Measured over the past years, SRT3 shows a quite strong growth in Revenue. The Revenue has been growing by 13.10% on average per year.
EPS 1Y (TTM)59.34%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%24.14%
Revenue 1Y (TTM)5.82%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%6.25%
3.2 Future
SRT3 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.28% yearly.
Based on estimates for the next years, SRT3 will show a quite strong growth in Revenue. The Revenue will grow by 8.99% on average per year.
EPS Next Y22.69%
EPS Next 2Y21.53%
EPS Next 3Y21.2%
EPS Next 5Y19.28%
Revenue Next Year5.43%
Revenue Next 2Y6.87%
Revenue Next 3Y8.23%
Revenue Next 5Y8.99%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 49.30 indicates a quite expensive valuation of SRT3.
SRT3's Price/Earnings ratio is rather expensive when compared to the industry. SRT3 is more expensive than 88.89% of the companies in the same industry.
When comparing the Price/Earnings ratio of SRT3 to the average of the S&P500 Index (25.07), we can say SRT3 is valued expensively.
With a Price/Forward Earnings ratio of 37.14, SRT3 can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRT3 indicates a rather expensive valuation: SRT3 more expensive than 83.33% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of SRT3 to the average of the S&P500 Index (34.08), we can say SRT3 is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.3 | ||
| Fwd PE | 37.14 |
4.2 Price Multiples
SRT3's Enterprise Value to EBITDA ratio is in line with the industry average.
SRT3's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.17 | ||
| EV/EBITDA | 22.21 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as SRT3's earnings are expected to grow with 21.20% in the coming years.
PEG (NY)2.17
PEG (5Y)N/A
EPS Next 2Y21.53%
EPS Next 3Y21.2%
5. Dividend
5.1 Amount
SRT3 has a yearly dividend return of 0.40%, which is pretty low.
SRT3's Dividend Yield is comparable with the industry average which is at 0.74.
Compared to an average S&P500 Dividend Yield of 2.44, SRT3's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.4% |
5.2 History
The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
SRT3 pays out 37.92% of its income as dividend. This is a sustainable payout ratio.
The dividend of SRT3 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP37.92%
EPS Next 2Y21.53%
EPS Next 3Y21.2%
FRA:SRT3 (11/21/2025, 5:29:52 PM)
224.8
+1.8 (+0.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners4.37%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.83B
Revenue(TTM)3.52B
Net Income(TTM)133.70M
Analysts80
Price Target342.38 (52.3%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.4% |
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP37.92%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.85%
Min EPS beat(2)-10.52%
Max EPS beat(2)4.83%
EPS beat(4)1
Avg EPS beat(4)-3.47%
Min EPS beat(4)-10.52%
Max EPS beat(4)4.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)0.83%
Revenue beat(4)3
Avg Revenue beat(4)1.91%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.71%
PT rev (3m)4.38%
EPS NQ rev (1m)3.45%
EPS NQ rev (3m)3.45%
EPS NY rev (1m)-0.47%
EPS NY rev (3m)-0.17%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)2.71%
Revenue NY rev (1m)0.28%
Revenue NY rev (3m)-0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.3 | ||
| Fwd PE | 37.14 | ||
| P/S | 4.79 | ||
| P/FCF | 35.17 | ||
| P/OCF | 19.25 | ||
| P/B | 6.31 | ||
| P/tB | N/A | ||
| EV/EBITDA | 22.21 |
EPS(TTM)4.56
EY2.03%
EPS(NY)6.05
Fwd EY2.69%
FCF(TTM)6.39
FCFY2.84%
OCF(TTM)11.68
OCFY5.19%
SpS46.97
BVpS35.63
TBVpS-35.24
PEG (NY)2.17
PEG (5Y)N/A
Graham Number60.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.39% | ||
| ROE | 5.01% | ||
| ROCE | 6.33% | ||
| ROIC | 4.71% | ||
| ROICexc | 4.98% | ||
| ROICexgc | 17.77% | ||
| OM | 14.06% | ||
| PM (TTM) | 3.8% | ||
| GM | 46.48% | ||
| FCFM | 13.61% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexgc growth 3Y-35.26%
ROICexgc growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.28 | ||
| Debt/FCF | 8.92 | ||
| Debt/EBITDA | 3.69 | ||
| Cap/Depr | 92.32% | ||
| Cap/Sales | 11.25% | ||
| Interest Coverage | 2.65 | ||
| Cash Conversion | 94.72% | ||
| Profit Quality | 357.97% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.49 | ||
| Altman-Z | 2.31 |
F-Score7
WACC7.95%
ROIC/WACC0.59
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)59.34%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%24.14%
EPS Next Y22.69%
EPS Next 2Y21.53%
EPS Next 3Y21.2%
EPS Next 5Y19.28%
Revenue 1Y (TTM)5.82%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%6.25%
Revenue Next Year5.43%
Revenue Next 2Y6.87%
Revenue Next 3Y8.23%
Revenue Next 5Y8.99%
EBIT growth 1Y18.65%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year99.69%
EBIT Next 3Y38.21%
EBIT Next 5Y26.8%
FCF growth 1Y123.33%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y6.61%
OCF growth 3Y4.07%
OCF growth 5Y20.79%
SARTORIUS AG-VORZUG / SRT3.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS AG-VORZUG (SRT3.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRT3.DE.
What is the valuation status for SRT3 stock?
ChartMill assigns a valuation rating of 2 / 10 to SARTORIUS AG-VORZUG (SRT3.DE). This can be considered as Overvalued.
Can you provide the profitability details for SARTORIUS AG-VORZUG?
SARTORIUS AG-VORZUG (SRT3.DE) has a profitability rating of 3 / 10.
Can you provide the PE and PB ratios for SRT3 stock?
The Price/Earnings (PE) ratio for SARTORIUS AG-VORZUG (SRT3.DE) is 49.3 and the Price/Book (PB) ratio is 6.31.
What is the expected EPS growth for SARTORIUS AG-VORZUG (SRT3.DE) stock?
The Earnings per Share (EPS) of SARTORIUS AG-VORZUG (SRT3.DE) is expected to grow by 22.69% in the next year.